Hutchmed (China) (HCM) said Friday that China's National Medical Products Administration granted conditional approval for the new drug application for Tazverik as a treatment for adult patients with relapsed or refractory follicular lymphoma.
The company said results of a phase 2 trial supported the conditional approval, with Tazverik demonstrating "promising efficacy." Hutchmed said the ongoing SYMPHONY-1 study is intended to be the confirmatory trial to validate Tazverik's clinical benefits.
Hutchmed is in charge of Tazverik's development and commercialization in China, Hong Kong, Macau and Taiwan, while Epizyme is the marketing authorization holder in China, according to the statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.